| Literature DB >> 29538313 |
Aaron Balasingam Koenig1,2, Juan Martín Barajas3, María Jose Guerrero4, Kalpana Ghoshal5.
Abstract
MicroRNAs are ~22 nucleotide RNAs that regulate gene expression at the post-transcriptional level by binding messenger RNA transcripts. miR-21 is described as an oncomiR whose steady-state levels are commonly increased in many malignancies, including hepatocellular carcinoma (HCC). Methods known as cross-linking and immunoprecipitation of RNA followed by sequencing (CLIP-seq) have enabled transcriptome-wide identification of miRNA interactomes. In our study, we use a publicly available Argonaute-CLIP dataset (GSE97061), which contains nine HCC cases with matched benign livers, to characterize the miR-21 interactome in HCC. Argonaute-CLIP identified 580 miR-21 bound target sites on coding transcripts, of which 332 were located in the coding sequences, 214 in the 3'-untranslated region, and 34 in the 5'-untranslated region, introns, or downstream sequences. We compared the expression of miR-21 targets in 377 patients with liver cancer from the data generated by The Cancer Genome Atlas (TCGA) and found that mRNA levels of 402 miR-21 targets are altered in HCC. Expression of three novel predicted miR-21 targets (CAMSAP1, DDX1 and MARCKSL1) correlated with HCC patient survival. Analysis of RNA-seq data from SK-Hep1 cells treated with a miR-21 antisense oligonucleotide (GSE65892) identified RMND5A, an E3 ubiquitin ligase, as a strong miR-21 candidate target. Collectively, our analysis identified novel miR-21 targets that are likely to play a causal role in hepatocarcinogenesis.Entities:
Keywords: HCC; liver cancer; miR-21; miRNA
Mesh:
Substances:
Year: 2018 PMID: 29538313 PMCID: PMC5877712 DOI: 10.3390/ijms19030851
Source DB: PubMed Journal: Int J Mol Sci ISSN: 1422-0067 Impact factor: 5.923
Figure 1Workflow for the selection and analysis of microRNA-21 (miR-21) targets. Unique miR-21 targets (n = 659) were identified using high-throughput sequencing of RNA isolated by cross-linking and immunoprecipitation of Argonaute (Ago-CLIP) data generated from matching benign liver and tumor tissues isolated from nine hepatocellular carcinoma (HCC) patients (GSE97061) [21]. Targets were sorted based on annotation of target loci: 5′ untranslated region [5′UTR], coding sequence [CDS], 3′ untranslated region [3′UTR], or other. Other groups included were transposable elements, introns, etc. Unique targets were compared to RNA-seq data generated by The Cancer Genome Atlas (TCGA) after log2 transformation and differential expression analysis between benign tissue and tumor tissue using the limma package in R [22]. Significance for differentially expressed genes was defined as having an adjusted p-value < 0.05 (n = 402).
Figure 2Binding sites for miR-21 are most commonly in the CDS and 3′UTR of mRNA with variation in binding motif frequency. miR-21 binding sites identified by Ago-CLIP were classified by the sign of their log-fold enrichment in HCC and by the location of miR-21 binding on the target transcript: 5′ untranslated region, CDS, 3′UTR or other (A). The binding sites of miR-21 were classified by the frequency of the target sequence motif (6mer, 7A1, 7m8, 8mer) at each annotated location (B). The distribution of sequence motifs varied between the CDS and the 3′UTR (p = 2.1 × 10−6).
Figure 3A low number of miR-21 sites are conserved among mice and humans. Targets in human livers or HCCs that precipitated miR-21 in Ago-CLIP (GSE97061) were compared to homolog gene identifiers from Ago-CLIP in mouse liver (GSE97058). Targets contained at least one binding site for miR-21 in the 5′UTR, CDS or 3′UTR (A). The number of binding sites at different locations in the mouse and human transcriptomes was compared (B).
Association between miR-21 expression and components of miR-21 interactome dysregulated after anti-sense miR-21 treatment in SK-Hep-1 cells.
| Gene Name | Full Name | miR-21 Expression | |
|---|---|---|---|
| Correlation Coefficient | Adjusted | ||
| Ankyrin repeat domain 46 | −0.36509 | 5.30 × 10−12 | |
| ADP ribosylation factor like GTPase 1 | 0.041021 | 1 | |
| Arrestin-domain containing 3 | −0.21111 | 3.96 × 10−3 | |
| Calmodulin-regulated spectrin-associated protein family member 2 | Not defined * | Not defined * | |
| cAMP responsive element binding protein 3 like 2 | 0.061419 | 1 | |
| Dimethylarginine dimethylaminohydrolase 1 | −0.340671 | 3.32 × 10−10 | |
| DEAD-box helicase 1 | 0.090883 | 1 | |
| Dual serine/threonine and tyrosine protein kinase | 0.237187 | 3.07 × 10−4 | |
| Egl-9 family hypoxia inducible factor 1 | 0.12549213 | 1 | |
| Guanylate-binding protein 1 | −0.0315479 | 1 | |
| Gamma-glutamyl carboxylase | −0.2833242 | 1.38 × 10−6 | |
| MARCKS like 1 | 0.27395541 | 4.52 × 10−6 | |
| Phosphoprotein membrane anchor with glycosphingolipid microdomains 1 | 0.23283137 | 4.86 × 10−4 | |
| PDZ domain containing 8 | −0.0632384 | 1 | |
| Pleckstrin homology domain containing A1 | −0.2021841 | 8.88 × 10−3 | |
| Required for meiotic nuclear division 5 homolog A | −0.5028372 | 0 | |
| Solute carrier family 46 member 3 | −0.4672836 | 0 | |
| SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily e, member 1 | 0.3145013 | 1.88 × 10−8 | |
| Spastic paraplegia 20 (Troyer syndrome) | −0.2245667 | 1.11 × 10−3 | |
| TBC1 domain family member 4 | −0.0978456 | 1 | |
| Transforming growth factor β receptor 2 | −0.1914894 | 0.0217 | |
| Thrombospondin 1 | −0.1524996 | 0.391 | |
| TIMP metallopeptidase inhibitor 3 | −0.1720478 | 0.0994 | |
| Tumor protein p63 regulated 1 like | −0.336802 | 6.19 × 10−10 | |
* Gene identifier could not be matched in expression data.
Expression of the miR-21 interactome and overall survival in 300 HCC patients.
| Gene Name | Overall Survival | |
|---|---|---|
| Cox Coefficient | Adjusted | |
| 0.341 | 0.012 | |
| 0.324 | 0.0171 | |
| 0.282 | 0.0256 | |
| 0.214 | 0.147 | |
| 0.121 | 0.408 | |
| 0.109 | 0.48 | |
| 0.097 | 0.543 | |
| 0.05 | 0.802 | |
| 0.04 | 0.836 | |
| 0.033 | 0.871 | |
| 0.017 | 0.936 | |
| 0.013 | 0.954 | |
| −0.006 | 0.976 | |
| −0.021 | 0.918 | |
| −0.037 | 0.866 | |
| −0.042 | 0.836 | |
| −0.069 | 0.687 | |
| −0.075 | 0.645 | |
| −0.099 | 0.514 | |
| −0.11 | 0.505 | |
| −0.104 | 0.493 | |
| −0.136 | 0.365 | |
| −0.212 | 0.135 | |
| −0.214 | 0.151 | |
Figure 4The expression data of the miR-21 interactome in tumor (n = 377) and matched normal tissue (n = 59) in patients with liver cancer were extracted from TCGA and compared to the tumor enrichment score determined by Ago-CLIP (A). Log2-fold enrichment of miR-21 targets by Ago-CLIP in HCC positively correlated with log2-fold expression change in tumor (p < 2.2 × 10−16). Genes whose expression in tumors negatively correlated with miR-21 expression were less enriched in HCC by Ago-CLIP than those with positive correlation (p < 2.2 × 10−16). Among miR-21 CDS targets, 64 genes were significantly downregulated and 173 genes were significantly upregulated (B). Among miR-21 3′UTR targets, 48 genes were significantly downregulated and 173 genes were significantly upregulated (C). Expression data for miR-21 targets in HCC were subjected to Ingenuity Pathway Analysis (IPA). Pathways predicted to be activated or inhibited by the miR-21 targetome are shown (D). Pathway significance was defined as having an adjusted p-value < 0.0005.
Figure 5Gene identifiers from transcripts in association with miR-21 identified by Argonaute-CLIP were matched to genes dysregulated in SK-Hep-1 cells after treatment with anti-miR-21 (GSE65892) [33]. The 24 common genes were considered potential miR-21 targets.